{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:14:13Z","timestamp":1794672853507,"version":"4.9.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Measuring adherence to PrEP (pre-exposure prophylaxis) remains challenging. Biological adherence measurements are reported to be more accurate than self-reports and pill counts but can be expensive and not suitable on a daily basis in resource-limited countries. Using data from a demonstration project on PrEP among female sex workers in Benin, we aimed to measure adherence to PrEP and compare self-report and pill count adherence to tenofovir (TFV) disoproxil fumarate (TDF) concentration in plasma to determine if these 2 measures are reliable and correlate well with biological adherence measurements.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Plasma TFV concentrations were analyzed in samples collected at day 14 follow-up visit and months 6, 12, 18, and 24 (or at last visit when follow-up was shorter). Self-reported adherence was captured at day 14 follow-up visit and then quarterly by asking participants to report the number of missed pills within the last week. For pill count, medications were refilled monthly and participants were asked to bring in their medication bottles at each follow-up visit. Using generalized estimating equations adherence measured by self-report and pill count was compared to plasma drug concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 255 participants, 47.1% completed follow-up. Weighted optimal adherence combining data from all visits was 26.8% for TFV concentration, 56.0% by self-report and 18.9% by pill count. Adherence measured by both TFV concentrations and self-report decreased over time (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.009 and <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.019, respectively), while the decreasing trend in adherence by pill count was not significant (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.087). The decrease in adherence was greater using TFV concentrations than the other 2 adherence measures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>With high levels of misreporting of adherence using self-report and pill count, the objective biomedical assessment of adherence via laboratory testing is optimal and more accurately reflects PrEP uptake and persistence. Alternative inexpensive and accurate approaches to monitor PrEP adherence should be investigated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020063","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T03:20:49Z","timestamp":1590636049000},"page":"e20063","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin"],"prefix":"10.1097","volume":"99","author":[{"given":"Aminata","family":"Mboup","sequence":"first","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Universit\u00e9 Laval"},{"name":"Centre de recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"B\u00e9hanzin","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Universit\u00e9 Laval"},{"name":"Dispensaire IST, Cotonou, B\u00e9nin"},{"name":"\u00c9cole Nationale de Formation des Techniciens Sup\u00e9rieurs en Sant\u00e9 Publique et en Surveillance \u00c9pid\u00e9miologique, Universit\u00e9 de Parakou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernand","family":"Gu\u00e9dou","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Universit\u00e9 Laval"},{"name":"Dispensaire IST, Cotonou, B\u00e9nin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Gigu\u00e8re","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Universit\u00e9 Laval"},{"name":"Centre de recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassirou","family":"Geraldo","sequence":"additional","affiliation":[{"name":"Dispensaire IST, Cotonou, B\u00e9nin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djimon Marcel","family":"Zannou","sequence":"additional","affiliation":[{"name":"Facult\u00e9 des sciences de la sant\u00e9, Universit\u00e9 d\u2019Abomey-Calavi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 K.","family":"K\u00eak\u00ea","sequence":"additional","affiliation":[{"name":"Programme Sant\u00e9 de Lutte contre le Sida (PSLS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa","family":"Bachabi","sequence":"additional","affiliation":[{"name":"Programme Sant\u00e9 de Lutte contre le Sida (PSLS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore","family":"Gangbo","sequence":"additional","affiliation":[{"name":"Programme Sant\u00e9 de Lutte contre le Sida (PSLS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dissou","family":"Affolabi","sequence":"additional","affiliation":[{"name":"Facult\u00e9 des sciences de la sant\u00e9, Universit\u00e9 d\u2019Abomey-Calavi"},{"name":"Centre national hospitalier universitaire HMK de Cotonou, B\u00e9nin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souleymane","family":"Diabat\u00e9","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Universit\u00e9 Laval"},{"name":"Centre de recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, Canada"},{"name":"Universit\u00e9 Alassane Ouattara, Bouak\u00e9, C\u00f4te d\u2019Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Alary","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Universit\u00e9 Laval"},{"name":"Centre de recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, Canada"},{"name":"Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"R1-20240521","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20240521","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/QAI.0000000000000158","article-title":"FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis","volume":"66","author":"Corneli","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-20240521","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"R4-20240521","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention","volume":"66","author":"Donnell","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-20240521","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"issue":"(Suppl 2)","key":"R6-20240521","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1097\/QAI.0b013e3182986f69","article-title":"Preexposure prophylaxis for HIV prevention: where have we been and where are we going?","volume":"63","author":"Baeten","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"(Suppl 1)","key":"R7-20240521","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1097\/01.qai.0000243112.91293.26","article-title":"The elusive gold standard. Future perspectives for HIV adherence assessment and intervention","volume":"43","author":"Chesney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-20240521","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/QAD.0000000000001024","article-title":"Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa","volume":"30","author":"Musinguzi","year":"2016","journal-title":"AIDS"},{"key":"R9-20240521","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","article-title":"Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm","volume":"29","author":"Haberer","year":"2015","journal-title":"AIDS"},{"key":"R10-20240521","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bcp.12194","article-title":"What are validated self-report adherence scales really measuring?: a systematic review","volume":"77","author":"Nguyen","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R11-20240521","doi-asserted-by":"crossref","first-page":"20642","DOI":"10.7448\/IAS.19.1.20642","article-title":"Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study","volume":"19","author":"van der Straten","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"R12-20240521","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10461-012-0172-7","article-title":"A proposal for quality standards for measuring medication adherence in research","volume":"17","author":"Williams","year":"2013","journal-title":"AIDS Behav"},{"key":"R13-20240521","doi-asserted-by":"crossref","first-page":"e0210791","DOI":"10.1371\/journal.pone.0210791","article-title":"Feasibility and acceptability of novel methods to estimate antiretroviral adherence: a longitudinal study","volume":"14","author":"Saberi","year":"2019","journal-title":"PLoS One"},{"key":"R14-20240521","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s10461-017-1951-y","article-title":"Utility of different adherence measures for PrEP: patterns and incremental value","volume":"22","author":"Abaasa","year":"2018","journal-title":"AIDS Behav"},{"key":"R15-20240521","doi-asserted-by":"crossref","first-page":"e0190118","DOI":"10.1371\/journal.pone.0190118","article-title":"Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial","volume":"13","author":"Baxi","year":"2018","journal-title":"PLoS One"},{"key":"R16-20240521","doi-asserted-by":"crossref","first-page":"e25208","DOI":"10.1002\/jia2.25208","article-title":"Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study","volume":"21","author":"Mboup","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"R18-20240521","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)","volume":"32","author":"Hendrix","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R19-20240521","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/EDE.0000000000000409","article-title":"Selection bias due to loss to follow up in cohort studies","volume":"27","author":"Howe","year":"2016","journal-title":"Epidemiology"},{"key":"R20-20240521","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R21-20240521","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0000000000001179","article-title":"An HIV preexposure prophylaxis demonstration project and safety study for young MSM","volume":"74","author":"Hosek","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-20240521","doi-asserted-by":"crossref","first-page":"e1002444","DOI":"10.1371\/journal.pmed.1002444","article-title":"HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: results from a prospective observational demonstration project","volume":"14","author":"Eakle","year":"2017","journal-title":"PLoS Med"},{"key":"R23-20240521","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/COH.0000000000000220","article-title":"Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice","volume":"11","author":"Haberer","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"R24-20240521","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10461-014-0859-z","article-title":"Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials","volume":"19","author":"Agot","year":"2015","journal-title":"AIDS Behav"},{"key":"R25-20240521","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000216","article-title":"Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection","volume":"66","author":"Amico","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-20240521","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2105\/AJPH.92.2.294","article-title":"The differential effects of face-to-face and computer interview modes","volume":"92","author":"Newman","year":"2002","journal-title":"Am J Public Health"},{"key":"R27-20240521","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ije\/dyq114","article-title":"A systematic review and meta-analysis of quantitative interviewing tools to investigate self-reported HIV and STI associated behaviours in low- and middle-income countries","volume":"39","author":"Phillips","year":"2010","journal-title":"Int J Epidemiol"},{"key":"R28-20240521","doi-asserted-by":"crossref","first-page":"e1001511","DOI":"10.1371\/journal.pmed.1001511","article-title":"Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa","volume":"10","author":"Haberer","year":"2013","journal-title":"PLoS Med"},{"key":"R29-20240521","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s10461-012-0268-0","article-title":"Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence","volume":"17","author":"Donnell","year":"2013","journal-title":"AIDS Behav"},{"key":"R30-20240521","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/QAI.0000000000002005","article-title":"Brief report: short-term adherence marker to PrEP predicts future nonretention in a large PrEP demo project: implications for point-of-care adherence testing","volume":"81","author":"Spinelli","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R32-20240521","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cpt.1201","article-title":"Pharmacologic-based methods of adherence assessment in HIV prevention","volume":"104","author":"Brooks","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R33-20240521","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0000000000001971","article-title":"Brief report: validation of a urine tenofovir immunoassay for adherence monitoring to PrEP and ART and establishing the cutoff for a point-of-care test","volume":"81","author":"Gandhi","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-20240521","first-page":"1647","article-title":"Urine tenofovir concentrations correlate with plasma and relates to TDF adherence: a randomized directly-observed pharmacokinetic trial (TARGET Study)","volume":"69","author":"Drain","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R35-20240521","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00216-019-02304-0","article-title":"Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring","volume":"412","author":"Pu","year":"2020","journal-title":"Anal Bioanal Chem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:04:16Z","timestamp":1716321856000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":33,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020063","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}